• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Curis Inc.

    2/12/24 4:16:14 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRIS alert in real time by email
    SC 13G 1 p24-0363sc13g.htm CURIS, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.  )*
     

    Curis, Inc.

    (Name of Issuer)
     

    Common Stock, $0.01 par value per share

    (Title of Class of Securities)
     

    231269309

    (CUSIP Number)
     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 23126920013GPage 2 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    M28 Capital Management LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    421,951

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    421,951

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    421,951

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.2%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

     

     

     

    CUSIP No. 23126920013GPage 3 of 7 Pages

     

     

    1

    NAMES OF REPORTING PERSONS

    Marc Elia

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    421,951

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    421,951

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    421,951

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.2%

    12

    TYPE OF REPORTING PERSON

    IN, HC

             

     

     

     

    CUSIP No. 23126920013GPage 4 of 7 Pages

     

     

     

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Curis, Inc. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 128 Spring Street, Building C, Suite 500, Lexington, MA 02421.

     

    Item 2(a). NAME OF PERSON FILING:

     

     

    This statement is filed by: (i) M28 Capital Management LP ("M28 Capital") with respect to the shares of Common Stock (as defined in Item 2(d)) held by M28 Capital Master Fund LP (the "M28 Fund") to which it acts as investment manager; and

     

    (ii) Marc Elia, the Chief Investment Officer of M28 Capital and Managing Member of M28 Capital Management GP LLC, the general partner of M28 Capital ("Mr. Elia", together with M28 Capital and M28 Capital Management GP, LLC, the "M28 Parties"), with respect to the shares of Common Stock held by the M28 Fund.

     

    Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."

     

    The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

      The principal business address of each of the M28 Parties is 700 Canal Street, 2nd Floor, Stamford, CT 06902.

     

    Item 2(c). CITIZENSHIP:
       
      M28 Capital is a Delaware limited partnership. Mr. Elia is a United States citizen.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common stock, $0.01 par value per share (the "Common Stock").

     

    Item 2(e). CUSIP NUMBER:
       
      231269309

     

     

     

    CUSIP No. 23126920013GPage 5 of 7 Pages

     

     

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) x

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).
     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:___________________________________________

     

    Item 4. OWNERSHIP:

     

       

    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons hereto and is incorporated herein by reference for each of the Reporting Persons.

     

    The percentages used in this Schedule 13G are calculated based upon 5,894,085 shares of Common Stock outstanding as of December 18, 2023, as reported in Amendment No. 1 to the Company’s Annual Report on Form 10-K/A for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission on December 21, 2023.

     

     

     

     

    CUSIP No. 23126920013GPage 6 of 7 Pages

     

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
       
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: o.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
       
      See Item 2.  The M28 Fund has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.  

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP:
       
      Not applicable.

     

    Item 10. CERTIFICATION:

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below, each of the Reporting Persons certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No. 23126920013GPage 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATED: February 12, 2024

     

     

    M28 Capital Management LP

     

      /s/ Christopher M. Taliercio
      Christopher M. Taliercio, President and Chief Compliance Officer
       
     

    /s/ Marc Elia

      MARC ELIA

     

     

     

     
     

    Exhibit 99.1

    JOINT FILING AGREEMENT
    PURSUANT TO RULE 13d-1(k)

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

    DATED: February 12, 2024

     

     

    M28 Capital Management LP

     

      /s/ Christopher M. Taliercio
      Christopher M. Taliercio, President and Chief Compliance Officer
       
     

    /s/ Marc Elia

      MARC ELIA

     

     

     

    Get the next $CRIS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRIS

    DatePrice TargetRatingAnalyst
    11/17/2023$26.00Buy
    Truist
    4/4/2022Outperform → Mkt Perform
    Raymond James
    10/13/2021$15.00Outperform
    Raymond James
    More analyst ratings

    $CRIS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Curis Inc.

      10-Q - CURIS INC (0001108205) (Filer)

      5/6/25 8:04:49 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CURIS INC (0001108205) (Filer)

      5/6/25 8:03:06 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Curis Inc.

      DEFA14A - CURIS INC (0001108205) (Filer)

      4/10/25 4:27:59 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRIS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CMO Hamdy Ahmed Md

      4 - CURIS INC (0001108205) (Issuer)

      5/5/25 4:26:25 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Hamdy Ahmed Md

      3 - CURIS INC (0001108205) (Issuer)

      5/5/25 4:24:56 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CFO Duvall Diantha

      4 - CURIS INC (0001108205) (Issuer)

      1/30/25 4:11:25 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRIS
    Financials

    Live finance-specific insights

    See more
    • Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025

      LEXINGTON, Mass., April 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can

      4/29/25 8:00:00 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025

      LEXINGTON, Mass., March 28, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its fourth quarter 2024 financial and operating results on Monday, March 31, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast c

      3/28/25 4:07:00 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024

      LEXINGTON, Mass., Nov. 7, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast

      11/7/24 8:00:00 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRIS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on Curis with a new price target

      Truist initiated coverage of Curis with a rating of Buy and set a new price target of $26.00

      11/17/23 7:37:50 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis downgraded by Raymond James

      Raymond James downgraded Curis from Outperform to Mkt Perform

      4/4/22 11:27:43 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James initiated coverage on Curis with a new price target

      Raymond James initiated coverage of Curis with a rating of Outperform and set a new price target of $15.00

      10/13/21 7:16:56 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRIS
    Leadership Updates

    Live Leadership Updates

    See more
    • Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations

      LEXINGTON, Mass., Jan. 3, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of three new executives to its management team. Joining the company, are Felix Geissler, M.D., Ph.D., as Vice President of Medical Affairs, Kimberly Steinmann, M.D., as Vice President of Clinical Development, and Dora Ferrari, as Vice President of Clinical Operations. They will be reporting directly to Dr. Reinhard von Roemeling, Senior Vice President, Clinical Devel

      1/3/22 8:00:00 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis Appoints John A. Hohneker, M.D. To Board Of Directors

      LEXINGTON, Mass., Dec. 6, 2021  /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of John A. Hohneker, M.D. to its Board of Directors. Dr. Hohneker brings 30 years of drug development and leadership experience within the biotech and pharmaceutical industries.  He most recently served as President and CEO of Anokion SA. Prior to Anokion, he was President of Research and Development at FORMA Therapeutics Inc., where he guided the company's transitio

      12/6/21 8:00:00 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      LEXINGTON, Mass., Jan. 8, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 4, 2021, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 185,000 shares of Curis common stock to three new employees, with a grant date of January 4, 2021 (the "Q1 2021 Inducement Grants"). Each of the Q1 2021 Inducement Grants has an exercise price per share equal to the closing price of the Company's common stock on January 4, 2021. Each stock option has a 10 year term and vests ov

      1/8/21 4:01:00 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRIS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Curis Inc.

      SC 13G/A - CURIS INC (0001108205) (Subject)

      11/13/24 2:05:06 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Curis Inc.

      SC 13G - CURIS INC (0001108205) (Subject)

      11/1/24 4:35:37 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Curis Inc.

      SC 13G - CURIS INC (0001108205) (Subject)

      4/15/24 2:12:19 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRIS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      LEXINGTON, Mass., May 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Board of Directors of Curis approved the grant of inducement stock options to its newly appointed Chief Medical Officer, Dr. Ahmed Hamdy to purchase 200,000 shares of Curis common stock, with a grant date of May 1, 2025 (the "Inducement Grant"). The Inducement Grant has an exercise price per share equal to the closing price of the Company's common stock

      5/6/25 6:16:00 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis Provides First Quarter 2025 Business Update

      Curis strengthens executive team with the appointment of industry veteran Dr. Ahmed Hamdy as Chief Medical Officer Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass., May 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the first quarter ended March 31, 2025. "I am pleased to announce the expansion of the Curis Executive Team with the addition of Dr. Ahmed Hamdy as

      5/6/25 8:00:00 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025

      LEXINGTON, Mass., April 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can

      4/29/25 8:00:00 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care